Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure

BACKGROUND AND PURPOSE: High plasma levels of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] were associated with improved outcome in a phase II clinical trial. Low bioavailability of 4-HPR has been limiting its therapeutic applications. This study characterized metabolism of 4-HPR in humans an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Jason P, Hwang, Kyunghwa, Singh, Hardeep, Wang, Dong, Reynolds, C Patrick, Curley, Robert W, Williams, Simon C, Maurer, Barry J, Kang, Min H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2011
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144539/
https://www.ncbi.nlm.nih.gov/pubmed/21391977
http://dx.doi.org/10.1111/j.1476-5381.2011.01310.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144539/
https://www.ncbi.nlm.nih.gov/pubmed/21391977
http://dx.doi.org/10.1111/j.1476-5381.2011.01310.x

Ejemplares similares